Arbutus Biopharma Corp (ABUS) is a pioneering biopharmaceutical company primarily focused on the discovery, development, and commercialization of a cure for people impacted by chronic Hepatitis B virus (HBV). This potentially life-threatening liver disease affects approximately 290 million people around the world. Headquartered in Warminster, Pennsylvania, the company has worldwide operations and multiple global partners, firmly positioning it as a global entity.
Arbutus has been operating since 2007 and it demonstrates dedication and commitment to its cause. Its primary objective is to develop a portfolio of therapies that enhances the potential of achieving a functional cure for chronic HBV, reducing the health burden and eventually eliminating the disease.
Under the leadership of President and CEO William H. Collier, Arbutus has assembled a diverse, experienced, and ambitious team focused meticulously on the objective of vanquishing HBV. The company's conviction that it can make a substantial difference to patients suffering from HBV is at the core of its ethos.
The company has a multi-product, multi-target approach to developing its innovative drug portfolio. This approach consists of identifying and combining drugs addressing different targets and mechanisms of action to maximize the probability of therapeutic success. The current pipeline features promising drug candidates including both small molecules and RNA-destabilizers that hold the potential to redefine the treatment landscape for HBV.
Arbutus Biopharma Corp does not devote itself solely to HBV research. It also has a proprietary lipid nanoparticle (LNP) technology which is licensed by major pharmaceutical companies for the delivery of nucleic acid-based drugs. This technology has proved to be pivotal in the development of life-saving therapies such as the COVID-19 vaccines developed by Moderna and Pfizer/BioNTech.
As an organization, Arbutus Biopharma Corp carries a responsibility beyond just profit-making. Its inherent drive for innovation, commitment to patient well-being, and dedication to transforming the future of HBV treatment represents the very essence of the company. With its strong strategic vision and remarkable potential in research and innovation, Arbutus is poised to undertake the transmutational journey from pioneering to leading in the biopharmaceutical industry.